<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Flucytosine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Flucytosine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Flucytosine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8451" href="/d/html/8451.html" rel="external">see "Flucytosine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12476" href="/d/html/12476.html" rel="external">see "Flucytosine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708774"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Monitoring:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use with extreme caution in patients with renal impairment. Close monitoring of hematologic, renal, and hepatic status of all patients is essential.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F171786"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ancobon</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1047411"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antifungal Agent, Systemic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462454"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Administer as part of an appropriate combination regimen to avoid development of flucytosine resistance. Doses provided are initial and should be adjusted based on therapeutic drug monitoring.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Body Weight</p></th>
<th align="left">
<p style="text-indent:0em;">Postnatal Age</p></th>
<th align="left">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">&lt;1 kg</p></td>
<td align="left">
<p style="text-indent:0em;">&lt;14 days</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg/kg/<b>day</b> in divided doses every 8 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">14 to 60 days</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg/kg/<b>day</b> in divided doses every 6 hours</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">1 to ≤2 kg</p></td>
<td align="left">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg/kg/<b>day</b> in divided doses every 8 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">8 to 60 days</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg/kg/<b>day</b> in divided doses every 6 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;2 kg</p></td>
<td align="left">
<p style="text-indent:0em;">≤60 days</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg/kg/<b>day</b> in divided doses every 6 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Reported dosing range: 25 to 150 mg/kg/<b>day</b> in divided doses every 6 to 24 hours; closely monitor serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2329429','lexi-content-ref-10987705','lexi-content-ref-6694869','lexi-content-ref-7803656']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2329429','lexi-content-ref-10987705','lexi-content-ref-6694869','lexi-content-ref-7803656'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da566d7b-7841-47eb-bd76-939d72a7ec9c">Candidal meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidal meningitis</b>: Limited data available: <b>Note: </b>Not routinely recommended; typically reserved for salvage therapy due to toxicity profile and unclear benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: Oral: 100 mg/kg/<b>day</b> in divided doses every 6 to 8 hours in combination with amphotericin B; usual reported range: 75 to 150 mg/kg/<b>day</b>; dosing based on a retrospective study and case reports including premature neonates (GA: 24 to 28 weeks; PMA at treatment: 26 to 29 weeks); dosing up to 200 mg/kg/<b>day</b> was reported in one preterm neonate (GA 32 weeks); treatment duration in some cases was up to 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24924877','lexi-content-ref-10987705','lexi-content-ref-26679628','lexi-content-ref-7803656','lexi-content-ref-19325555','lexi-content-ref-583082','lexi-content-ref-6522917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24924877','lexi-content-ref-10987705','lexi-content-ref-26679628','lexi-content-ref-7803656','lexi-content-ref-19325555','lexi-content-ref-583082','lexi-content-ref-6522917'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F171809"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Administer as part of an appropriate combination regimen to avoid development of flucytosine resistance. Doses provided are initial and should be adjusted based on therapeutic drug monitoring.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: Oral: 25 mg/kg/dose every 6 hours as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58122c93-3f4f-4de9-93bd-5b9a14cc4cd1">Aspergillosis, endocarditis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, endocarditis: </b>Limited data available: <b>Note: </b>Flucytosine is not included in IDSA guidelines for management of aspergillosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 37.5 mg/kg/dose every 6 hours in combination with amphotericin B (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chorioretinitis:</i> Infants, Children, and Adolescents: Oral: 25 mg/kg/dose every 6 hours in combination with amphotericin B (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS disease, treatment:</i> Infants, Children, and Adolescents: Oral: 25 mg/kg/dose every 6 hours in combination with amphotericin B (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endocarditis or implanted cardiovascular device: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants: Oral: 25 mg/kg/dose every 6 hours in combination with amphotericin B; valve replacement or removal of hardware is strongly recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: 25 to 37.5 mg/kg/dose every 6 hours in combination with amphotericin B; valve replacement or removal of hardware is strongly recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection:</i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Cystitis, symptomatic: Oral: 25 mg/kg/dose every 6 hours for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pyelonephritis: Oral: 25 mg/kg/dose every 6 hours for 2 weeks with or without amphotericin B (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>); if fungal balls present, use in combination with amphotericin B and treatment duration should be until symptom resolution and clear urine culture.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64c40883-de7e-4d2a-b509-cc6823b5c363">Cryptococcal disease; disseminated; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcal disease; disseminated (including CNS disease); treatment (independent of HIV status):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 25 mg/kg/dose every 6 hours as part of an appropriate combination regimen. Duration of induction therapy is ≥2 weeks and is dependent upon multiple factors including immune or HIV status, source of infection and concomitant antifungal therapy; induction therapy should be followed by consolidation and maintenance therapy with fluconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2','lexi-content-ref-20047480','lexi-content-ref-18582201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2','lexi-content-ref-20047480','lexi-content-ref-18582201'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51110617"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidance has been used by some clinicians:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents without HIV infection:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Dosing adjustment based on a usual initial dose of 25 to 37.5 mg/kg/dose every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). Doses should be adjusted based on therapeutic drug monitoring.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Oral: 25 to 37.5 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Oral: 25 to 37.5 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Oral: 25 to 37.5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis or peritoneal dialysis: Oral: 25 to 37.5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents with HIV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing adjustment based on a usual dose of 25 mg/kg/dose every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>); doses should be adjusted based on therapeutic drug monitoring.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;40 mL/minute: No adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;20 to 40 mL/minute: Oral: 25 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 20 mL/minute: Oral: 25 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Oral: 25 mg/kg/dose every 48 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Oral: 25 to 50 mg/kg every 48 to 72 hours; administer dose after hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51110618"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, flucytosine has minimal hepatic metabolism; use caution.</p></div>
<div class="block doa drugH1Div" id="F171790"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8451" href="/d/html/8451.html" rel="external">see "Flucytosine: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b>
<b>Oral:</b> 50 to 150 mg/kg/day in divided doses every 6 hours.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cardiac infection, native or prosthetic valve endocarditis, or device infection (eg, implantable cardiac defibrillator, pacemaker, ventricular assist device):</i>
<b> Oral: </b>25 mg/kg/dose 4 times daily (in combination with an amphotericin B lipid formulation). For device infection without endocarditis, duration is 4 weeks after device removal for generator pocket infections and ≥6 weeks after device removal for wire infections. For endocarditis, duration is ≥6 weeks after valve replacement surgery, with longer durations for perivalvular abscesses or other complications. <b>Note:</b> May transition to step-down therapy with fluconazole in patients with fluconazole-susceptible isolates who are clinically stable with negative repeat blood cultures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Central nervous system (eg, meningitis):</i>
<b>Oral:</b> 25 mg/kg/dose 4 times daily (in combination with amphotericin B [liposomal]) until step-down therapy is clinically appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endophthalmitis (with or without vitritis):</i> Fluconazole- or voriconazole-resistant isolates: <b>Oral: </b>25 mg/kg/dose 4 times daily (in combination with amphotericin B [liposomal]) for ≥4 to 6 weeks until examination indicates resolution; for patients with vitritis or with macular involvement, intravitreal antifungal therapy is also recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cystitis, symptomatic:</i>
<b>Oral: </b>Fluconazole-resistant <i>C. glabrata</i>: 25 mg/kg/dose 4 times daily for 7 to 10 days as monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pyelonephritis:</i> Fluconazole-resistant <i>C. glabrata</i>: <b>Oral: </b>25 mg/kg/dose 4 times daily in combination with amphotericin B deoxycholate for 1 to 7 days or as monotherapy for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Vulvovaginal, caused by C.</i>
<i> glabrata (alternative agent) (off-label use):</i>
<b>Intravaginal:</b> 16% extemporaneously compounded cream: 1 applicatorful (~5 g) once daily (at bedtime) for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3772900','lexi-content-ref-26679628','lexi-content-ref-14634557','lexi-content-ref-Sobel.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3772900','lexi-content-ref-26679628','lexi-content-ref-14634557','lexi-content-ref-Sobel.2018'])">Ref</a></span>). <b>Note:</b> Reserve for patients with no other clear cause of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sobel.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sobel.2018'])">Ref</a></span>). May also be used in combination with intravaginal amphotericin B (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-11402233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-11402233'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="861d43ac-1525-43a9-9303-2c3c8553eeb6">Cryptococcal meningitis, disseminated disease, or severe pulmonary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcal meningitis, disseminated disease, or severe pulmonary infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Induction: 25 mg/kg/dose 4 times daily, as part of an appropriate combination regimen. Duration of induction therapy is ≥2 weeks, but should be extended in patients with evidence of neurological complications; for cerebral cryptococcomas, recommended duration is ≥6 weeks. Induction therapy is followed by consolidation and maintenance therapy with fluconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900315','lexi-content-ref-HHS.1','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900315','lexi-content-ref-HHS.1','lexi-content-ref-20047480'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992013"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The manufacturer recommends dose reduction for elevated BUN or serum creatinine (or other signs of renal impairment); however, no specific dosage adjustments are provided. The following adjustments have been recommended (based on a usual dose of 25 mg/kg/dose every 6 hours):</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;40 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-20047480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 21 to 40 mL/minute: 25 mg/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 20 mL/minute: 25 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: 25 mg/kg/dose every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease on intermittent hemodialysis: 25 to 50 mg/kg/dose every 48 to 72 hours; administer dose after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drew.1','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drew.1','lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989260"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F171751"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiotoxicity, chest pain, ventricular dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin photosensitivity, skin rash, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia, hypokalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, duodenal ulcer, enterocolitis, gastrointestinal hemorrhage, nausea, ulcerative colitis, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azotemia, crystalluria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia, aplastic anemia, bone marrow aplasia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (acute), hepatic necrosis, increased liver enzymes, increased serum bilirubin, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, ataxia, confusion, fatigue, hallucination, headache, paresthesia, parkinsonism, peripheral neuropathy, psychosis, sedated state, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, kidney failure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Gastrointestinal: Colitis (Sohail 2014)</p></div>
<div class="block coi drugH1Div" id="F171769"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to flucytosine or any component of the formulation; known complete dihydropyrimidine dehydrogenase enzyme deficiency.</p></div>
<div class="block war drugH1Div" id="F171748"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic disease: Use with caution in patients with bone marrow depression, hematologic disease, or those who have been treated with radiation or drugs that suppress the bone marrow; bone marrow toxicity may be dose related and irreversible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; hepatotoxicity that appears to be dose related may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Dosage adjustment recommended in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Dihydropyrimidine dehydrogenase enzyme deficiency: Severe toxicity, including diarrhea, mucositis, neurotoxicity, and neutropenia, may be increased in patients with dihydropyrimidine dehydrogenase enzyme deficiency; consider determination of dihydropyrimidine dehydrogenase enzyme deficiency in patients who develop drug toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Monotherapy: Generally should not be used as monotherapy, as resistance can rapidly develop.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878458"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Serum flucytosine concentrations are highly variable in neonates and tend to be higher in children &lt;12 years of age; monitor closely (Baley 1990; Pasqualotto 2007; Soltani 2006).</p></div>
<div class="block foc drugH1Div" id="F171760"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ancobon: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F171744"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F171771"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ancobon Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $92.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $178.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Flucytosine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $82.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $158.81</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block exp drugH1Div" id="F171767"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;">
<b>50 mg/mL Oral Suspension (ASHP standard concentration) </b>(ASHP 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">A 50 mg/mL oral suspension may be made with capsules and OraPlus and OraSweet SF. Mix 30 mL of OraPlus and 30 mL of OraSweet SF together in a separate container. Empty the contents of six 500 mg capsules in a mortar; add 15 mL portion of the vehicle mixture and triturate. Transfer mixture to a 60 mL (2 ounce) amber prescription bottle. Rinse the mortar with an additional 15 mL of vehicle mixture and pour into the amber bottle. Repeat rinsing procedure until a final bottle volume of 60 mL is achieved. Label the bottle "shake well." Stable for 90 days at 3°C to 5°C (37°F to 41°F) or 23°C to 25°C (73°F to 77°F).</p>
<div class="reference">VandenBussche HL, Johnson CE, Yun J, et al. Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations. <i>Am J Health Syst Pharm</i>. 2002;93(19):1853-1855.<span class="pubmed-id">12374070</span></div>
<p style="text-indent:0em;">
<b>10 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 10 mg/mL oral suspension may be made with capsules and distilled water. Empty the contents of ten 500 mg capsules in a mortar; add small portions of distilled water and mix to a uniform paste. Mix while adding distilled water in incremental proportions to <b>almost</b> 500 mL; transfer to a 500 mL volumetric flask, rinse mortar several times with distilled water, and add sufficient quantity of distilled water to make 500 mL. Store in glass or plastic prescription bottles and label "shake well". Stable for 70 days refrigerated and 14 days at room temperature.</p>
<div class="reference">Wintermeyer SM and Nahata MC. Stability of Flucytosine in an Extemporaneously Compounded Oral Liquid. <i>Am J Health Syst Pharm</i>. 1996;53(4):407-409.<span class="pubmed-id">8673661</span></div>
<p style="text-indent:0em;">
<b>16% intravaginal cream</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 16% cream may be made with fourteen 500 mg capsules; open into a mortar and reduce to fine powder. Levigate powder with glycerin to form a smooth paste; add to hydrophilic ointment base or cold cream for a total weight of 45 g. Blend until smooth and transfer to two 2-ounce ointment tubes. Instruct patient to insert mixture into 6.4 g vaginal applicator prior to use (Horowitz 1986).</p>
<div class="reference">
<a name="3772900"></a>Horowitz BJ. Topical flucytosine therapy for chronic recurrent Candida tropicalis infections. <i>J Reprod Med</i>. 1986;31(9):821-824.<span class="pubmed-id">3772900</span></div>
</div>
<div class="block admp drugH1Div" id="F52612850"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: To reduce or avoid nausea and vomiting, administer a few capsules at a time over 15 minutes until full dose is taken.</p></div>
<div class="block adm drugH1Div" id="F171765"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> To reduce or avoid nausea and vomiting, administer a few capsules at a time over 15 minutes until full dose is taken.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vaginal (off-label route):</b> Gently insert full applicator of cream and press plunger to release the medication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3772900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3772900'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F171781"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at room temperature of 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53566952"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of serious infections caused by susceptible strains of Candida (eg, candidemia, endocarditis, pulmonary infections, urinary tract infections) and/or Cryptococcus (eg, meningitis, pulmonary infections, cryptococcemia, urinary tract infections) in combination with amphotericin B (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F171828"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flucytosine may be confused with fludarabine, fluorouracil </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ancobon may be confused with Oncovin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299342"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F171753"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: May enhance the adverse/toxic effect of Flucytosine. Amphotericin B may increase the serum concentration of Flucytosine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Flucytosine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cytarabine (Conventional): May diminish the therapeutic effect of Flucytosine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gimeracil: May increase serum concentrations of the active metabolite(s) of Flucytosine. Specifically, gimeracil may increase concentrations of fluorouracil.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F171782"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases the rate, but not the extent of absorption.</p></div>
<div class="block pri drugH1Div" id="F171772"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies. Flucytosine is metabolized to fluorouracil which may cause adverse events if administered during pregnancy; refer to the Fluorouracil (Systemic) monograph for additional information.</p></div>
<div class="block mopp drugH1Div" id="F53566937"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to therapy: Serum electrolytes (especially potassium), CBC with differential, BUN, and SCr.</p>
<p style="text-indent:-2em;margin-left:2em;">During therapy: Serum electrolytes, SCr, BUN, alkaline phosphatase, AST, ALT, CBC with differential, and serum flucytosine concentrations. If serum flucytosine concentrations cannot be monitored, monitor CBC at least twice weekly (HHS [OI adult] 2022). Monitor for GI upset and rash.</p></div>
<div class="block rerp drugH1Div" id="F53566598"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Timing: </b>Peak serum concentrations are routinely recommended; obtain at steady-state after initiation of a new regimen (eg, within 3 to 5 days of therapy), following dosage adjustments, and as clinically indicated (eg, change in kidney function, bone marrow toxicity). Trough concentrations may also be monitored for avoidance of resistance development or to allow pharmacokinetic calculations (AST-ID COP [Baddley 2019]; BSMM [Ashbee 2014]; Downes 2020; IDSA [Pappas 2016]; IDSA [Perfect 2010]; HHS [OI adult] 2022; HHS [OI pediatric] 2022; <i>Red Book</i> [AAP 2021].</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peak</i>: Collect sample 2 hours after oral dose administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Trough</i>: If obtained, collect sample at the end of the dosing interval (ie, 6 hours after oral dose administration), just prior to next dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Target: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peak (2-hour):</i> ≤100 mg/L (to avoid bone marrow toxicity and hepatotoxicity); a target of 30 to 80 mg/L has also been suggested (AST-ID COP [Baddley 2019]; Bradley 2022; Gómez-López 2020; IDSA [Pappas 2016]; IDSA [Perfect 2010]; <i>Red Book</i> [AAP 2021]). Peak concentrations of 40 to 60 mg/L have also been recommended for pediatric patients with HIV and cryptococcal disease (HHS [OI pediatric] 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Trough:</i> Recommendations are variable; targets of 25 to 50 mg/L or &gt;20 to 40 mg/L have been suggested; see institutional protocol (BSMM [Ashbee 2014]; Downes 2020; Gómez-López 2020; Vermes 2000). Trough concentrations &lt;25 mg/L may be associated with development of resistance, though data are limited and study evaluated flucytosine monotherapy (Normark 1972). For treatment of candidiasis in neonates, time above MIC of &gt;40% (with trough concentration of 5 to 10 mg/L) has also been recommended (Bradley 2022).</p></div>
<div class="block pha drugH1Div" id="F171747"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Penetrates fungal cells and is converted to fluorouracil; after further bioconversion, it competes with uridylic acid, interfering with fungal RNA and protein synthesis, and inhibits thymidylate synthetase, inhibiting fungal DNA synthesis (Vermes 2000).</p></div>
<div class="block phk drugH1Div" id="F171768"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Into CSF, aqueous humor, joints, peritoneal fluid; V<sub>d</sub>: 0.6 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 3% to 4%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimally hepatic; deaminated both in yeasts and possibly via gut bacteria to 5-fluorouracil.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 78% to 89%; decreased in neonates.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: 4 to 34 hours (Baley 1990).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 7.4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 2 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Anuria: 85 hours (range: 30 to 250).</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD): 75 to 200 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: 2.5 ± 1.3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&gt;90% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51192581"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Prolonged half-life (29.9 to 250 hours in anuric or nephrectomized patients).</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Serum flucytosine concentrations are highly variable in neonates and tend to be higher in children &lt;12 years of age; monitor closely (Baley 1990; Pasqualotto 2007; Soltani 2006).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038617"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ancobon | Ancotil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ancobon</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alcobon</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Alcobon | Ancobon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ancotil | Ancotil Roche</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ancobon</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ancobon</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ancotil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ancobon.1">
<a name="Ancobon.1"></a>Ancobon (flucytosine) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. American College of Physicians; 2007:70, 158.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24379304">
<a name="24379304"></a>Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. <i>J Antimicrob Chemother</i>. 2014;69(5):1162-1176. doi:10.1093/jac/dkt508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/24379304/pubmed" id="24379304" target="_blank">24379304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900315">
<a name="30900315"></a>Baddley JW, Forrest GN; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation - guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13543. doi:10.1111/ctr.13543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/30900315/pubmed" id="30900315" target="_blank">30900315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2329429">
<a name="2329429"></a>Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, Outcome of Treatment, and Toxic Effects of Amphotericin B and 5-Fluorocytosine in Neonates. <i>J Pediatr</i>. 1990;116(5):791-797.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/2329429/pubmed" id="2329429" target="_blank">2329429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24924877">
<a name="24924877"></a>Barton M, O'Brien K, Robinson JL, et al. Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. <i>BMC Infect Dis</i>. 2014;14:327. doi:10.1186/1471-2334-14-327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/24924877/pubmed" id="24924877" target="_blank">24924877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31974859">
<a name="31974859"></a>Downes KJ, Fisher BT, Zane NR. Administration and dosing of systemic antifungal agents in pediatric patients. <i>Paediatr Drugs</i>. 2020;22(2):165-188. doi:10.1007/s40272-020-00379-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/31974859/pubmed" id="31974859" target="_blank">31974859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drew.1">
<a name="Drew.1"></a>Drew RH, Perfect JR. Flucytosine. In: Yu VL, Merigan TC, Barriere SL, eds. <i>Antimicrobial therapy and vaccines</i>. Williams and Wilkins; 1999:1170-1184.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10987705">
<a name="10987705"></a>Fernandez M, Moylett EH, Noyola DE, et al. Candidal Meningitis in Neonates: A 10-Year Review. <i>Clin Infect Dis</i>. 2000;31(2):458-463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/10987705/pubmed" id="10987705" target="_blank">10987705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32535150">
<a name="32535150"></a>Gómez-López A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. <i>Clin Microbiol Infect</i>. 2020;26(11):1481-1487. doi:10.1016/j.cmi.2020.05.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/32535150/pubmed" id="32535150" target="_blank">32535150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother</i>. 2012;67(2):269-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3772900">
<a name="3772900"></a>Horowitz BJ. Topical flucytosine therapy for chronic recurrent Candida tropicalis infections. <i>J Reprod Med</i>. 1986;31(9):821-824.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/3772900/pubmed" id="3772900" target="_blank">3772900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6694869">
<a name="6694869"></a>Johnson DE, Thompson TR, Green TP, Ferrieri P. Systemic candidiasis in very low-birth-weight infants (less than 1,500 grams). <i>Pediatrics</i>. 1984;73(2):138-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/6694869/pubmed" id="6694869" target="_blank">6694869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7573192">
<a name="7573192"></a>Lau AH, Kronfol NO. Elimination of Flucytosine by Continuous Hemofiltration. <i>Am J Nephrol</i>. 1995;15(4):327-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/7573192/pubmed" id="7573192" target="_blank">7573192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1379913">
<a name="1379913"></a>Lyman CA, Walsh TJ. Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications. <i>Drugs</i>. 1992;44(1):9-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/1379913/pubmed" id="1379913" target="_blank">1379913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7803656">
<a name="7803656"></a>Marr B, Gross S, Cunningham C, et al. Candidal Sepsis and Meningitis in a Very-Low-Birth-Weight Infant Successfully Treated With Fluconazole and Flucytosine. <i>Clin Infect Dis</i>. 1994;19(4):795-796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/7803656/pubmed" id="7803656" target="_blank">7803656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4597703">
<a name="4597703"></a>Normark S, Schönebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. <i>Antimicrob Agents Chemother</i>. 1972;2(3):114-121. doi:10.1128/AAC.2.3.114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/4597703/pubmed" id="4597703" target="_blank">4597703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19325555">
<a name="19325555"></a>Pahud BA, Greenhow TL, Piecuch B, et al. Preterm Neonates With Candidal Brain Microabscesses: A Case Series. <i>J Perinatol</i>. 2009;29(4):323-326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/19325555/pubmed" id="19325555" target="_blank">19325555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679628">
<a name="26679628"></a>Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi:10.1093/cid/civ933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/26679628/pubmed" id="26679628" target="_blank">26679628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17339279">
<a name="17339279"></a>Pasqualotto AC, Howard SJ, Moore CB, et al. Flucytosine Therapeutic Monitoring: 15 Years Experience From the UK. <i>J Antimicrob Chemother</i>. 2007;59(4):791-793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/17339279/pubmed" id="17339279" target="_blank">17339279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9868423">
<a name="9868423"></a>Patel R. Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine. <i>Mayo Clin Proc</i>. 1998;73(12):1205-1225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/9868423/pubmed" id="9868423" target="_blank">9868423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27365388">
<a name="27365388"></a>Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;63(4):e1-e60. doi: 10.1093/cid/ciw326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/27365388/pubmed" id="27365388" target="_blank">27365388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047480">
<a name="20047480"></a>Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(3):291-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/20047480/pubmed" id="20047480" target="_blank">20047480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-583082">
<a name="583082"></a>Rao HK, Myers GJ. Candida meningitis in the newborn. <i>South Med J</i>. 1979;72(11):1468-1471. doi: 10.1097/00007611-197911000-00036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/583082/pubmed" id="583082" target="_blank">583082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10770733">
<a name="10770733"></a>Saag MS, Graybill RJ, Larsen RA, et al. Practice Guidelines for the Management of Cryptococcal Disease. Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2000;30(4):710-718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/10770733/pubmed" id="10770733" target="_blank">10770733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6522917">
<a name="6522917"></a>Smego RA Jr, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. <i>Rev Infect Dis</i>. 1984;6(6):791-801. doi: 10.1093/clinids/6.6.791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/6522917/pubmed" id="6522917" target="_blank">6522917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sobel.2018">
<a name="Sobel.2018"></a>Sobel JD. Candida vulvovaginitis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14634557">
<a name="14634557"></a>Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. <i>Am J Obstet Gynecol</i>. 2003;189(5):1297-1300. doi:10.1067/s0002-9378(03)00726-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/14634557/pubmed" id="14634557" target="_blank">14634557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777084">
<a name="24777084"></a>Sohail MA, Ikram U. Flucytosine-induced colitis. <i>BMJ Case Rep</i>. 2014;2014:bcr2013203381. doi:10.1136/bcr-2013-203381<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/24777084/pubmed" id="24777084" target="_blank">24777084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17085019">
<a name="17085019"></a>Soltani M, Tobin CM, Bowker KE, et al. Evidence of Excessive Concentrations of 5-Flucytosine in Children Aged Below 12 Years: A 12-Year Review of Serum Concentrations From a UK Clinical Assay Reference Laboratory. <i>Int J Antimicrob Agents</i>. 2006;28(6):574-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/17085019/pubmed" id="17085019" target="_blank">17085019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18582201">
<a name="18582201"></a>Tunkel AR, Glaser CA, Bloch KC, et al. The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;47(3):303-327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/18582201/pubmed" id="18582201" target="_blank">18582201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Updated September 28, 2022. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated September 2, 2022. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12374070">
<a name="12374070"></a>VandenBussche HL, Johnson CE, Yun J, et al. Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations. <i>Am J Health Syst Pharm</i>. 2002;93(19):1853-1855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/12374070/pubmed" id="12374070" target="_blank">12374070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10933638">
<a name="10933638"></a>Vermes A, Guchelaar H, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. <i>J Antimicrob Chemother</i>. 2000;46(2):171-179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/10933638/pubmed" id="10933638" target="_blank">10933638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11402233">
<a name="11402233"></a>White DJ, Habib AR, Vanthuyne A, Langford S, Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. <i>Sex Transm Infect</i>. 2001;77(3):212-213. doi:10.1136/sti.77.3.212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/11402233/pubmed" id="11402233" target="_blank">11402233</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13304 Version 228.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
